Selected research
Industry Research
Total Intravenous Anesthesia (TIVA) Industry Research Report 2026
Market perspective
The global Total Intravenous Anesthesia (TIVA) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Total Intravenous Anesthesia (TIVA) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Total Intravenous Anesthesia (TIVA) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Total Intravenous Anesthesia (TIVA) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Total Intravenous Anesthesia (TIVA) include Mylan, Hengrui, B. Braun Medical, AbbVie, Astrazeneca, Piramal, Nhwa, Maruishi and Lunan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Total Intravenous Anesthesia (TIVA) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Total Intravenous Anesthesia (TIVA) Market by Company
Mylan
Hengrui
B. Braun Medical
AbbVie
Astrazeneca
Piramal
Nhwa
Maruishi
Lunan
Hikma Pharmaceuticals
Fresenius-Kabi
Baxter Healthcare
Total Intravenous Anesthesia (TIVA) Segment by Type
Barbiturates
Propofol
Midazolam
Etomidate
Others
Total Intravenous Anesthesia (TIVA) Segment by Application
Orthopedic
Cosmetic Surgeries
Predominantly Emergency
Others
Total Intravenous Anesthesia (TIVA) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Total Intravenous Anesthesia (TIVA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Total Intravenous Anesthesia (TIVA) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Total Intravenous Anesthesia (TIVA).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Total Intravenous Anesthesia (TIVA) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Total Intravenous Anesthesia (TIVA) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Total Intravenous Anesthesia (TIVA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Barbiturates
- Propofol
- Midazolam
- Etomidate
- Others
Applications
- Orthopedic
- Cosmetic Surgeries
- Predominantly Emergency
- Others
Companies covered
- Mylan
- Hengrui
- B. Braun Medical
- AbbVie
- Astrazeneca
- Piramal
- Nhwa
- Maruishi
- Lunan
- Hikma Pharmaceuticals
- Fresenius-Kabi
- Baxter Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Total Intravenous Anesthesia (TIVA) Market Size (2021-2032)
- 2.2.2 Global Total Intravenous Anesthesia (TIVA) Sales (2021-2032)
- 2.2.3 Global Total Intravenous Anesthesia (TIVA) Market Average Price (2021-2032)
- 2.3 Total Intravenous Anesthesia (TIVA) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Barbiturates
- 2.3.3 Propofol
- 2.3.4 Midazolam
- 2.3.5 Etomidate
- 2.3.6 Others
- 2.4 Total Intravenous Anesthesia (TIVA) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Orthopedic
- 2.4.3 Cosmetic Surgeries
- 2.4.4 Predominantly Emergency
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Total Intravenous Anesthesia (TIVA) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Total Intravenous Anesthesia (TIVA) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Total Intravenous Anesthesia (TIVA) Revenue of Manufacturers (2021-2026)
- 3.4 Global Total Intravenous Anesthesia (TIVA) Average Price by Manufacturers (2021-2026)
- 3.5 Global Total Intravenous Anesthesia (TIVA) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Total Intravenous Anesthesia (TIVA), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Total Intravenous Anesthesia (TIVA), Product Type & Application
- 3.8 Global Manufacturers of Total Intravenous Anesthesia (TIVA), Established Date
- 3.9 Global Total Intravenous Anesthesia (TIVA) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mylan
- 4.1.1 Mylan Company Information
- 4.1.2 Mylan Business Overview
- 4.1.3 Mylan Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mylan Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.1.5 Mylan Recent Developments
- 4.2 Hengrui
- 4.2.1 Hengrui Company Information
- 4.2.2 Hengrui Business Overview
- 4.2.3 Hengrui Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Hengrui Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.2.5 Hengrui Recent Developments
- 4.3 B. Braun Medical
- 4.3.1 B. Braun Medical Company Information
- 4.3.2 B. Braun Medical Business Overview
- 4.3.3 B. Braun Medical Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 B. Braun Medical Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.3.5 B. Braun Medical Recent Developments
- 4.4 AbbVie
- 4.4.1 AbbVie Company Information
- 4.4.2 AbbVie Business Overview
- 4.4.3 AbbVie Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AbbVie Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.4.5 AbbVie Recent Developments
- 4.5 Astrazeneca
- 4.5.1 Astrazeneca Company Information
- 4.5.2 Astrazeneca Business Overview
- 4.5.3 Astrazeneca Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Astrazeneca Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.5.5 Astrazeneca Recent Developments
- 4.6 Piramal
- 4.6.1 Piramal Company Information
- 4.6.2 Piramal Business Overview
- 4.6.3 Piramal Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Piramal Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.6.5 Piramal Recent Developments
- 4.7 Nhwa
- 4.7.1 Nhwa Company Information
- 4.7.2 Nhwa Business Overview
- 4.7.3 Nhwa Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Nhwa Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.7.5 Nhwa Recent Developments
- 4.8 Maruishi
- 4.8.1 Maruishi Company Information
- 4.8.2 Maruishi Business Overview
- 4.8.3 Maruishi Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Maruishi Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.8.5 Maruishi Recent Developments
- 4.9 Lunan
- 4.9.1 Lunan Company Information
- 4.9.2 Lunan Business Overview
- 4.9.3 Lunan Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Lunan Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.9.5 Lunan Recent Developments
- 4.10 Hikma Pharmaceuticals
- 4.10.1 Hikma Pharmaceuticals Company Information
- 4.10.2 Hikma Pharmaceuticals Business Overview
- 4.10.3 Hikma Pharmaceuticals Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hikma Pharmaceuticals Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.10.5 Hikma Pharmaceuticals Recent Developments
- 4.11 Fresenius-Kabi
- 4.11.1 Fresenius-Kabi Company Information
- 4.11.2 Fresenius-Kabi Business Overview
- 4.11.3 Fresenius-Kabi Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Fresenius-Kabi Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.11.5 Fresenius-Kabi Recent Developments
- 4.12 Baxter Healthcare
- 4.12.1 Baxter Healthcare Company Information
- 4.12.2 Baxter Healthcare Business Overview
- 4.12.3 Baxter Healthcare Total Intravenous Anesthesia (TIVA) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Baxter Healthcare Total Intravenous Anesthesia (TIVA) Product Portfolio
- 4.12.5 Baxter Healthcare Recent Developments
5 Global Total Intravenous Anesthesia (TIVA) Market Scenario by Region
- 5.1 Global Total Intravenous Anesthesia (TIVA) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Total Intravenous Anesthesia (TIVA) Sales by Region: 2021-2032
- 5.2.1 Global Total Intravenous Anesthesia (TIVA) Sales by Region: 2021-2026
- 5.2.2 Global Total Intravenous Anesthesia (TIVA) Sales by Region: 2027-2032
- 5.3 Global Total Intravenous Anesthesia (TIVA) Revenue by Region: 2021-2032
- 5.3.1 Global Total Intravenous Anesthesia (TIVA) Revenue by Region: 2021-2026
- 5.3.2 Global Total Intravenous Anesthesia (TIVA) Revenue by Region: 2027-2032
- 5.4 North America Total Intravenous Anesthesia (TIVA) Market Facts & Figures by Country
- 5.4.1 North America Total Intravenous Anesthesia (TIVA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Total Intravenous Anesthesia (TIVA) Sales by Country (2021-2032)
- 5.4.3 North America Total Intravenous Anesthesia (TIVA) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Total Intravenous Anesthesia (TIVA) Market Facts & Figures by Country
- 5.5.1 Europe Total Intravenous Anesthesia (TIVA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Total Intravenous Anesthesia (TIVA) Sales by Country (2021-2032)
- 5.5.3 Europe Total Intravenous Anesthesia (TIVA) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Total Intravenous Anesthesia (TIVA) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Total Intravenous Anesthesia (TIVA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Total Intravenous Anesthesia (TIVA) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Total Intravenous Anesthesia (TIVA) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Total Intravenous Anesthesia (TIVA) Market Facts & Figures by Country
- 5.7.1 South America Total Intravenous Anesthesia (TIVA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Total Intravenous Anesthesia (TIVA) Sales by Country (2021-2032)
- 5.7.3 South America Total Intravenous Anesthesia (TIVA) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Total Intravenous Anesthesia (TIVA) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Total Intravenous Anesthesia (TIVA) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Total Intravenous Anesthesia (TIVA) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Total Intravenous Anesthesia (TIVA) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Total Intravenous Anesthesia (TIVA) Sales by Type (2021-2032)
- 6.1.1 Global Total Intravenous Anesthesia (TIVA) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Total Intravenous Anesthesia (TIVA) Sales Market Share by Type (2021-2032)
- 6.2 Global Total Intravenous Anesthesia (TIVA) Revenue by Type (2021-2032)
- 6.2.1 Global Total Intravenous Anesthesia (TIVA) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Total Intravenous Anesthesia (TIVA) Revenue Market Share by Type (2021-2032)
- 6.3 Global Total Intravenous Anesthesia (TIVA) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Total Intravenous Anesthesia (TIVA) Sales by Application (2021-2032)
- 7.1.1 Global Total Intravenous Anesthesia (TIVA) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Total Intravenous Anesthesia (TIVA) Sales Market Share by Application (2021-2032)
- 7.2 Global Total Intravenous Anesthesia (TIVA) Revenue by Application (2021-2032)
- 7.2.1 Global Total Intravenous Anesthesia (TIVA) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Total Intravenous Anesthesia (TIVA) Revenue Market Share by Application (2021-2032)
- 7.3 Global Total Intravenous Anesthesia (TIVA) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Total Intravenous Anesthesia (TIVA) Value Chain Analysis
- 8.1.1 Total Intravenous Anesthesia (TIVA) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Total Intravenous Anesthesia (TIVA) Production Mode & Process
- 8.2 Total Intravenous Anesthesia (TIVA) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Total Intravenous Anesthesia (TIVA) Distributors
- 8.2.3 Total Intravenous Anesthesia (TIVA) Customers
9 Global Total Intravenous Anesthesia (TIVA) Analyzing Market Dynamics
- 9.1 Total Intravenous Anesthesia (TIVA) Industry Trends
- 9.2 Total Intravenous Anesthesia (TIVA) Industry Drivers
- 9.3 Total Intravenous Anesthesia (TIVA) Industry Opportunities and Challenges
- 9.4 Total Intravenous Anesthesia (TIVA) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst